Functional kinomics identifies candidate therapeutic targets in head and neck cancer

Russell Moser, Chang Xu, Michael Kao, James Annis, Luisa Angelica Lerma, Christopher M. Schaupp, Kay E. Gurley, In Sock Jang, Asel Biktasova, Wendell G. Yarbrough, Adam Margolin, Carla Grandori, Christopher J. Kemp, Eduardo Méndez

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Purpose: To identify novel therapeutic drug targets for p53-mutant head and neck squamous cell carcinoma (HNSCC). Experimental Design: RNAi kinome viability screens were performed on HNSCC cells, including autologous pairs from primary tumor and recurrent/metastatic lesions, and in parallel on murine squamous cell carcinoma (MSCC) cells derived from tumors of inbred mice bearing germline mutations in Trp53, and p53 regulatory genes: Atm, Prkdc, and p19 Arf. Cross-species analysis of cell lines stratified by p53 mutational status and metastatic phenotype was used to select 38 kinase targets. Both primary and secondary RNAi validation assays were performed on additional HNSCC cell lines to credential these kinase targets using multiple phenotypic endpoints. Kinase targets were also examined via chemical inhibition using a panel of kinase inhibitors. A preclinical study was conducted on the WEE1 kinase inhibitor, MK-1775. Results: Our functional kinomics approach identified novel survival kinases in HNSCC involved in G2-M cell-cycle checkpoint, SFK, PI3K, and FAK pathways. RNAi-mediated knockdown and chemical inhibition of the WEE1 kinase with a specific inhibitor, MK-1775, had a significant effect on both viability and apoptosis. Sensitivity to the MK-1775 kinase inhibitor is in part determined by p53 mutational status, and due to unscheduled mitotic entry. MK-1775 displays single-agent activity and potentiates the efficacy of cisplatin in a p53-mutant HNSCC xenograft model. Conclusions: WEE1 kinase is a potential therapeutic drug target for HNSCC. This study supports the application of a functional kinomics strategy to identify novel therapeutic targets for cancer.

Original languageEnglish (US)
Pages (from-to)4274-4288
Number of pages15
JournalClinical Cancer Research
Volume20
Issue number16
DOIs
StatePublished - Aug 15 2014
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Phosphotransferases
RNA Interference
Therapeutics
G2 Phase Cell Cycle Checkpoints
Cell Line
Neoplasms
Germ-Line Mutation
p53 Genes
Regulator Genes
Phosphatidylinositol 3-Kinases
Heterografts
Pharmaceutical Preparations
Cisplatin
Carcinoma, squamous cell of head and neck
Squamous Cell Carcinoma
Research Design
Apoptosis
Phenotype
MK 1775

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Moser, R., Xu, C., Kao, M., Annis, J., Lerma, L. A., Schaupp, C. M., ... Méndez, E. (2014). Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clinical Cancer Research, 20(16), 4274-4288. https://doi.org/10.1158/1078-0432.CCR-13-2858

Functional kinomics identifies candidate therapeutic targets in head and neck cancer. / Moser, Russell; Xu, Chang; Kao, Michael; Annis, James; Lerma, Luisa Angelica; Schaupp, Christopher M.; Gurley, Kay E.; Jang, In Sock; Biktasova, Asel; Yarbrough, Wendell G.; Margolin, Adam; Grandori, Carla; Kemp, Christopher J.; Méndez, Eduardo.

In: Clinical Cancer Research, Vol. 20, No. 16, 15.08.2014, p. 4274-4288.

Research output: Contribution to journalArticle

Moser, R, Xu, C, Kao, M, Annis, J, Lerma, LA, Schaupp, CM, Gurley, KE, Jang, IS, Biktasova, A, Yarbrough, WG, Margolin, A, Grandori, C, Kemp, CJ & Méndez, E 2014, 'Functional kinomics identifies candidate therapeutic targets in head and neck cancer', Clinical Cancer Research, vol. 20, no. 16, pp. 4274-4288. https://doi.org/10.1158/1078-0432.CCR-13-2858
Moser, Russell ; Xu, Chang ; Kao, Michael ; Annis, James ; Lerma, Luisa Angelica ; Schaupp, Christopher M. ; Gurley, Kay E. ; Jang, In Sock ; Biktasova, Asel ; Yarbrough, Wendell G. ; Margolin, Adam ; Grandori, Carla ; Kemp, Christopher J. ; Méndez, Eduardo. / Functional kinomics identifies candidate therapeutic targets in head and neck cancer. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 16. pp. 4274-4288.
@article{19fa211bbf574c0681fac8a9a371f65d,
title = "Functional kinomics identifies candidate therapeutic targets in head and neck cancer",
abstract = "Purpose: To identify novel therapeutic drug targets for p53-mutant head and neck squamous cell carcinoma (HNSCC). Experimental Design: RNAi kinome viability screens were performed on HNSCC cells, including autologous pairs from primary tumor and recurrent/metastatic lesions, and in parallel on murine squamous cell carcinoma (MSCC) cells derived from tumors of inbred mice bearing germline mutations in Trp53, and p53 regulatory genes: Atm, Prkdc, and p19 Arf. Cross-species analysis of cell lines stratified by p53 mutational status and metastatic phenotype was used to select 38 kinase targets. Both primary and secondary RNAi validation assays were performed on additional HNSCC cell lines to credential these kinase targets using multiple phenotypic endpoints. Kinase targets were also examined via chemical inhibition using a panel of kinase inhibitors. A preclinical study was conducted on the WEE1 kinase inhibitor, MK-1775. Results: Our functional kinomics approach identified novel survival kinases in HNSCC involved in G2-M cell-cycle checkpoint, SFK, PI3K, and FAK pathways. RNAi-mediated knockdown and chemical inhibition of the WEE1 kinase with a specific inhibitor, MK-1775, had a significant effect on both viability and apoptosis. Sensitivity to the MK-1775 kinase inhibitor is in part determined by p53 mutational status, and due to unscheduled mitotic entry. MK-1775 displays single-agent activity and potentiates the efficacy of cisplatin in a p53-mutant HNSCC xenograft model. Conclusions: WEE1 kinase is a potential therapeutic drug target for HNSCC. This study supports the application of a functional kinomics strategy to identify novel therapeutic targets for cancer.",
author = "Russell Moser and Chang Xu and Michael Kao and James Annis and Lerma, {Luisa Angelica} and Schaupp, {Christopher M.} and Gurley, {Kay E.} and Jang, {In Sock} and Asel Biktasova and Yarbrough, {Wendell G.} and Adam Margolin and Carla Grandori and Kemp, {Christopher J.} and Eduardo M{\'e}ndez",
year = "2014",
month = "8",
day = "15",
doi = "10.1158/1078-0432.CCR-13-2858",
language = "English (US)",
volume = "20",
pages = "4274--4288",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Functional kinomics identifies candidate therapeutic targets in head and neck cancer

AU - Moser, Russell

AU - Xu, Chang

AU - Kao, Michael

AU - Annis, James

AU - Lerma, Luisa Angelica

AU - Schaupp, Christopher M.

AU - Gurley, Kay E.

AU - Jang, In Sock

AU - Biktasova, Asel

AU - Yarbrough, Wendell G.

AU - Margolin, Adam

AU - Grandori, Carla

AU - Kemp, Christopher J.

AU - Méndez, Eduardo

PY - 2014/8/15

Y1 - 2014/8/15

N2 - Purpose: To identify novel therapeutic drug targets for p53-mutant head and neck squamous cell carcinoma (HNSCC). Experimental Design: RNAi kinome viability screens were performed on HNSCC cells, including autologous pairs from primary tumor and recurrent/metastatic lesions, and in parallel on murine squamous cell carcinoma (MSCC) cells derived from tumors of inbred mice bearing germline mutations in Trp53, and p53 regulatory genes: Atm, Prkdc, and p19 Arf. Cross-species analysis of cell lines stratified by p53 mutational status and metastatic phenotype was used to select 38 kinase targets. Both primary and secondary RNAi validation assays were performed on additional HNSCC cell lines to credential these kinase targets using multiple phenotypic endpoints. Kinase targets were also examined via chemical inhibition using a panel of kinase inhibitors. A preclinical study was conducted on the WEE1 kinase inhibitor, MK-1775. Results: Our functional kinomics approach identified novel survival kinases in HNSCC involved in G2-M cell-cycle checkpoint, SFK, PI3K, and FAK pathways. RNAi-mediated knockdown and chemical inhibition of the WEE1 kinase with a specific inhibitor, MK-1775, had a significant effect on both viability and apoptosis. Sensitivity to the MK-1775 kinase inhibitor is in part determined by p53 mutational status, and due to unscheduled mitotic entry. MK-1775 displays single-agent activity and potentiates the efficacy of cisplatin in a p53-mutant HNSCC xenograft model. Conclusions: WEE1 kinase is a potential therapeutic drug target for HNSCC. This study supports the application of a functional kinomics strategy to identify novel therapeutic targets for cancer.

AB - Purpose: To identify novel therapeutic drug targets for p53-mutant head and neck squamous cell carcinoma (HNSCC). Experimental Design: RNAi kinome viability screens were performed on HNSCC cells, including autologous pairs from primary tumor and recurrent/metastatic lesions, and in parallel on murine squamous cell carcinoma (MSCC) cells derived from tumors of inbred mice bearing germline mutations in Trp53, and p53 regulatory genes: Atm, Prkdc, and p19 Arf. Cross-species analysis of cell lines stratified by p53 mutational status and metastatic phenotype was used to select 38 kinase targets. Both primary and secondary RNAi validation assays were performed on additional HNSCC cell lines to credential these kinase targets using multiple phenotypic endpoints. Kinase targets were also examined via chemical inhibition using a panel of kinase inhibitors. A preclinical study was conducted on the WEE1 kinase inhibitor, MK-1775. Results: Our functional kinomics approach identified novel survival kinases in HNSCC involved in G2-M cell-cycle checkpoint, SFK, PI3K, and FAK pathways. RNAi-mediated knockdown and chemical inhibition of the WEE1 kinase with a specific inhibitor, MK-1775, had a significant effect on both viability and apoptosis. Sensitivity to the MK-1775 kinase inhibitor is in part determined by p53 mutational status, and due to unscheduled mitotic entry. MK-1775 displays single-agent activity and potentiates the efficacy of cisplatin in a p53-mutant HNSCC xenograft model. Conclusions: WEE1 kinase is a potential therapeutic drug target for HNSCC. This study supports the application of a functional kinomics strategy to identify novel therapeutic targets for cancer.

UR - http://www.scopus.com/inward/record.url?scp=84905985785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905985785&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-2858

DO - 10.1158/1078-0432.CCR-13-2858

M3 - Article

VL - 20

SP - 4274

EP - 4288

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 16

ER -